Tnk / Auditoria EM SAUDE

16/03/2025

Innovative Strategy for Resistant Depression and Suicidal Ideation: HEOR Analysis From the Perspective of BRAZIL / LATAM / LMIC .
Author(s)
ELIO TANAKA, Sr., MD1, ELAINE BREGOLA, RESEARCHER2, Helena Maria Romcy, MSc, MD2, Goldete Priszkulnik, MSc, MD2, JOSE MARIO JUNIOR, RESEARCHER2.
1MEDICAL AUDIT, TNK MEDICAL AUDIT INSTITUTION, CURITIBA, Brazil, 2TNK, CURITIBA PR, Brazil.
OBJECTIVES: We study the chance of a possible decrease in su***de ideation rates, based on scientific data and informations from a promising innovation strategy based on clinical end point.
METHODS: From database of the Notifiable Diseases Information System (SINAN) & Su***de data from the Mortality Information System (SIM) of the year 2022. A total of 496,583 cases of su***de from 2019 to 2022 in Brazilian scenario and a su***de attempt due to exogenous intoxication a subtotal of 4,259 cases, in one specific State (Brazil ). Data from international literature showing a strategy using esketamine intranasal and antidepressant treatment decreased: the risk of relapse by 51% (Hazard Ratio [HR], 0.49; 95% ci, 0.29-0.84) among patients who achieved stable remission, and 70% (HR, 0.30; 95% ci, 0.16-0.55) among those who achieved stable response compared to treatment with antidepressants and placebo.
RESULTS: We speculate that 51% (Hazard Ratio [HR] of 496,583 CASES, means that esketamine and antidepressant treatment decreased the risk of relapse to avoidance risk of suicidal ideation in 253.257 cases. The 2,172 / 4,259 cases of attempted su***de reported in exogenous intoxication data, could contemplate the chances of rescue from “de novo" treatments and better clinical outcomes.
CONCLUSIONS: For patients who have experienced remission or response after treatment with esketamine, there is a chance to resume a new treatment protocol in order to avoid loss of life or loss of productivity in cases of sequelae/su***de attempt. However, lengthy follow-up is needed in order to answer to this, with regard to economic impact and other outcomes.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1

Code
HSD32

Topic
Health Service Delivery & Process of Care

Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Mental Health (including addition), SDC: Neurological Disorders, STA: Alternative Medicine

28/02/2025

Dear ELIO TANAKA,

Congratulations! We are pleased to inform you that abstract 496 titled A New Device for Early Detection of Breast Disease: Stakeholders Perspective Analysis in Brazil/LATAM/LMIC has been accepted as a Poster Presentation to ISPOR 2025 taking place May 13-16. ISPOR 2025 will be held in-person at the Montreal Convention Centre, Montreal, QC, Canada.

28/02/2025

Dear ELIO TANAKA,

Congratulations! We are pleased to inform you that abstract 3775 titled Innovative Strategy for Resistant Depression and Suicidal Ideation: HEOR Analysis From the Perspective of BRAZIL / LATAM / LMIC . has been accepted as a Poster Presentation to ISPOR 2025 taking place May 13-16. ISPOR 2025 will be held in-person at the Montreal Convention Centre, Montreal, QC, Canada

28/02/2025

Caro ELIO TANAKA,

Parabéns! Temos o prazer de informar que o resumo 743 intitulado Analysis of the Human Development Index by Innovation In Health, Through the Incorporation of New Technologies In Oncology: Preliminary Data in LMIC/LATAM/Brazil foi aceito como uma apresentação de pôster para o ISPOR 2025 , que ocorrerá de 13 a 16 de maio. O ISPOR 2025 será realizado presencialmente no Montreal Convention Centre , Montreal, QC, Canadá.

28/02/2025

Diversidade e inclusão na ISPOR
A ISPOR está fortemente comprometida com a diversidade. O Plano Estratégico e os valores essenciais da Sociedade abraçam a excelência por meio do incentivo e aceitação de ideias, culturas e disciplinas diversas. As submissões de pesquisa são incentivadas por todas as partes interessadas e são avaliadas com base no mérito. A ISPOR também visa refletir a diversidade de seus membros em todos os esforços e incentiva a consideração da diversidade em submissões de resumos. As dimensões da diversidade incluem (mas não se limitam a) gênero, estágio de carreira, etnia, raça, educação, orientação sexual, região/localização geográfica, deficiências e religião. Informações adicionais podem ser encontradas na Política de Diversidade da Sociedade em www.ispor.org/diversitypolicy .

ISPOR is a Society firmly committed to the advancement of health economics and outcomes research (HEOR) based on sound methods and scientific excellence. ISPOR believes that diversity and inclusion are foundational principles for achieving our mission, and that diversity and inclusion are valuable a...

28/02/2025

Caro ELIO TANAKA,

Parabéns! Temos o prazer de informar que o resumo 742 intitulado Análise de Custo-Efetividade de Inovação Tecnológica para Feridas Crônicas: Modelo Farmacoeconômico Baseado em Ferramentas LOGIT e MAIC foi aceito como Apresentação em Pôster para a ISPOR 2025 , que ocorrerá de 13 a 16 de maio. A ISPOR 2025 será realizada presencialmente no Centro de Convenções de Montreal , Montreal, QC, Canadá. Este e-mail contém informações importantes sobre sua sessão, próximos prazos e itens de ação importantes.

INFORMAÇÕES SOBRE A SESSÃO

Sessão de pôsteres: Sessão de pôsteres 5

Código do pôster: CO172

Data/Hora da Sessão de Pôsteres: Sexta-feira, 16 de maio, 9h00 - 11h30

Período de discussão: 9:00 - 10:00 AM

11/02/2025

MENSAGEM DA ORGANIZAÇÃO
O 8º Fórum de Farmacoeconomia e Inovação em Saúde será realizado em formato presencial nos dias 24 e 25 de abril de 2025.

O formato online foi um sucesso, mas recebemos diversos pedidos para realização presencial, enriquecendo mais os debates e proporcionando troca de experiências nos intervalos e principalmente o calor humano.

Esperamos receber cerca de 300 profissionais de todo o Brasil para esta edição do Fórum.

Reserve esta data na sua agenda, e venha trazer as questões da sua empresa e descobrir as opiniões dos participantes.

11/02/2025

https://www.farmacoeconomia.com.br/temario.asp

05/12/2024

Improving Healthcare Decisions
ISPOR is dedicated to improving healthcare decision making. We believe that every healthcare decision should be informed by the best scientific research. Toward that goal, the Society’s mission is to advance health economics and outcomes research excellence to improve decision making for health globally.

03/12/2024

Budget Impact of Tezepelumab for the Treatment of Severe Asthma in the Brazilian Private Healthcare System
Author(s)
Diegoli H1, Dias C2, Furtado D3
1Academia VBHC, Joinville, SC, Brazil, 2AstraZeneca do Brasil, São Paulo, SP, Brazil, 3UNIMED SERRANA RJ, Nova Friburgo, RJ, Brazil

Presentation Documents
Poster - Budget impact of Tezepelumab (published version)142333.pdf
OBJECTIVES: Asthma, a chronic inflammatory condition of the airways, affects about 20 million people in Brazil, with 5%–10% of cases classified as severe, leading to significant morbidity and high healthcare utilization. Biologic drugs have transformed the management of severe asthma. In Brazil, available medications include omalizumab for severe allergic asthma (SAA), mepolizumab and benralizumab for severe eosinophilic asthma (SEA), and dupilumab for T2-high asthma. However, despite the use of these immunobiologics, unmet needs persist in patients with severe asthma. The PATHFINDER clinical program has demonstrated the effectiveness and safety of tezepelumab for severe asthma, irrespective of phenotype or biomarker. To evaluate the incorporation of tezepelumab into the Brazilian supplementary health system, a budget impact model (BIM) was developed.

METHODS: The BIM, with a 5-year time horizon, assessed costs from the perspective of the supplementary healthcare system. Eligible patients had uncontrolled severe asthma (including SEA and SAA), with the total population defined by epidemiological parameters. List prices for tezepelumab and its comparators were sourced from Brazil’s Medicines Market Regulation Chamber (CMED), including an 18% tax. The projected market share of treatments was based on market research. The study adhered to the Brazilian Guidelines for Budget Impact Analysis.

RESULTS: Over 5 years, the estimated number of eligible patients increased from 6,133 to 6,318. The incorporation of tezepelumab resulted in 491 to 1,769 patients receiving the treatment over this period, leading to a cost reduction of -BRL 19,480,911 . The cost reduction was more pronounced in SAA (-BRL 18,888,169) than in SEA (-BRL 592,742). Sensitivity analyses revealed that the cost of tezepelumab followed by the cost of omalizumab exhibited the highest sensitivity. A more rapid incorporation (920 to 2,691 patients) resulted in a total cost reduction of -BRL 33,385,321.

CONCLUSIONS: The inclusion of tezepelumab led to significantly lower medical expenses, highlighting its dual clinical and cost-saving impact.

03/12/2024

The Role of Mindfulness, Pelvic Floor Physical Therapy (PFPT), and Hypopressive Exercises for Chronic Pelvic Pain (CPP): Preliminary Results in Productivity Gain and Loss
Author(s)
Bittelbrunn CC1, Tanaka F1, Tanaka J1, Pauka Mello GV1, Tanaka E2
1TNK Health Care, Curitiba , Pr, Brazil, 2TNK Health Economics Outcome Research Brazil, CURITIBA, Brazil

OBJECTIVES: This study aimed to analyze the results in productivity gain and loss in a sample of a population with chronic pelvic pain (CPP) after mindfulness, pelvic floor physical therapy (PFPT) and hypopressive exercises.

METHODS: The controlled clinical trial included women with chronic pelvic pain who were separated into two groups. Each group initially underwent a health promotion protocol based on mindfulness or pelvic floor physical therapy (a structured protocol with electrotherapy, biofeedback, trigger point massage, and basic pelvic kinesiotherapy guidance). After the first intervention, each group underwent the other type of therapy, so that all participants underwent both interventions. In the hypopressive exercise group, given the irregularity of the sample and adhesion, we had difficulties in the material, but assertiveness of gains reported.

RESULTS: Of the 49 women included, 38 participated in both interventions and were evaluated in 4 moments. Sociodemographic and clinical characteristics did not differ significantly between groups. Some results have suggested that performing physical therapy first is more effective, while others have suggested the opposite. Some showed similar gains, regardless of the initial therapy, and still others showed that the sum of the interventions provided progressive improvement and significant. On the follow-up, gains were sustained in more than 85% of the 29 domains. In the hypopressive group, the data need to be refined, although favorable results have been obtained.

CONCLUSIONS: Our results suggest that multidisciplinary treatment consisting of: mindfulness, pelvic floor physiotherapy (PFPT) and hypopressive exercises are safe and effective for CPD, as it improves pain, plus daily productivity gain as a consequence. As a limitation of the study, we identified , quantitative in terms of comparative scores and suggestions for future research, leaving here the recommendation for larger prospective multicenter studies, with or without simultaneous interventions to optimize results.